Aptose Biosciences Inc.

corporate_fare Company Profile

Aptose Biosciences Inc.

APTOF·OTC·Life Sciences·CIK 0000882361

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines for cancer, primarily in the United States. The company's main clinical-stage product is tuspetinib (HM43239), a once-daily oral kinase inhibitor. Tuspetinib has completed Phase 1/2 clinical trials and targets specific kinases involved in myeloid malignancies, including acute myeloid leukemia and higher-risk myelodysplastic syndromes. Aptose Biosciences Inc. holds license agreements with the National Cancer Institute for the clinical development of tuspetinib and with Hanmi Pharmaceutical Co Ltd. for its research, development, and commercialization. The company, incorporated in 1986, was previously known as Lorus Therapeutics Inc. before changing its name to Aptose Biosciences Inc. in August 2014. Its headquarters are located in Toronto, Canada.

Aptose Biosciences Inc. (OTC:APTOF) is a publicly traded company in the Life Sciences sector. Wiseek monitors APTOF SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Aptose Biosciences Acquisition by Hanmi Pharmaceutical Finalized; Delisting Imminent (2026-06-30)
Aptose's AML Drug Shows 86% Remission, 100% in TP53-Mutated Patients in Phase 1/2 Trial (2026-06-15)
Aptose Biosciences: Hanmi Acquisition Delayed, Deepening Cash Crisis (2026-05-29)
Aptose Biosciences Reports $7.63M Q1 Net Loss, No Revenue, Amid Cash Concerns (2026-05-13)
Aptose Biosciences Warns of Insufficient Cash to Fund Operations (2026-05-13)

Browse all tickers starting with A →

show_chartPrice Chart

Loading chart...

feed APTOF - Latest Insights

Filing Type

Date Range

APTOF

Jun 30, 2026, 7:32 PM EDT

Source: GlobeNewswire

Importance Score:

Aptose Biosciences Acquisition by Hanmi Pharmaceutical Finalized; Delisting Imminent

Price at Filing: $1.62

Real-time Price: $1.69

Change: +$0.070 (+4%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Jun 15, 2026, 7:30 AM EDT

Source: GlobeNewswire

Importance Score:

Aptose's AML Drug Shows 86% Remission, 100% in TP53-Mutated Patients in Phase 1/2 Trial

Price at Filing: $1.61

Real-time Price: $1.69

Change: +$0.0775 (+5%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

APTOF

May 29, 2026, 8:04 AM EDT

Source: Reuters

Importance Score:

Aptose Biosciences: Hanmi Acquisition Delayed, Deepening Cash Crisis

Price at Filing: $1.57

Real-time Price: $1.69

Change: +$0.120 (+8%)

Market Cap: $4.314M

Sentiment: Negative

View Wiseek Article

APTOF

May 13, 2026, 5:21 PM EDT

Source: Wiseek News

Importance Score:

Aptose Biosciences Reports $7.63M Q1 Net Loss, No Revenue, Amid Cash Concerns

Price at Filing: $1.70

Real-time Price: $1.69

Change: -$0.010 (-0.59%)

Market Cap: $4.314M

Sentiment: Negative

View Wiseek Article

APTOF

May 13, 2026, 5:07 PM EDT

Source: Dow Jones Newswires

Importance Score:

Aptose Biosciences Warns of Insufficient Cash to Fund Operations

Price at Filing: $1.70

Real-time Price: $1.69

Change: -$0.010 (-0.59%)

Market Cap: $4.314M

Sentiment: Negative

View Wiseek Article

APTOF

Mar 31, 2026, 5:29 PM EDT

Filing Type: 10-K

Importance Score:

Shareholders Approve Hanmi Acquisition Amidst Going Concern Warning

Price at Filing: $1.67

Real-time Price: $1.69

Change: +$0.024 (+1%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

APTOF

Mar 31, 2026, 5:23 PM EDT

Filing Type: 8-K

Importance Score:

Aptose Biosciences Secures Final Court Approval for Hanmi Acquisition, Reports Positive Clinical Data

Price at Filing: $1.67

Real-time Price: $1.69

Change: +$0.024 (+1%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

APTOF

Mar 31, 2026, 4:59 PM EDT

Filing Type: 8-K

Importance Score:

Shareholders Approve Hanmi Pharmaceutical Acquisition with Strong Majority

Price at Filing: $1.67

Real-time Price: $1.69

Change: +$0.024 (+1%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

APTOF

Mar 23, 2026, 7:30 AM EDT

Filing Type: 8-K

Importance Score:

Glass Lewis Recommends Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition

Price at Filing: $1.61

Real-time Price: $1.69

Change: +$0.079 (+5%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

APTOF

Mar 19, 2026, 7:40 AM EDT

Filing Type: 8-K

Importance Score:

ISS Recommends Aptose Biosciences Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition

Price at Filing: $1.64

Real-time Price: $1.69

Change: +$0.048 (+3%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

APTOF

Feb 23, 2026, 9:36 PM EST

Filing Type: 8-K

Importance Score:

Aptose Biosciences Updates Acquisition Timeline, Secures $11.1M Financing from Acquirer Hanmi

Price at Filing: $1.62

Real-time Price: $1.69

Change: +$0.070 (+4%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Feb 23, 2026, 8:26 PM EST

Filing Type: SC 13E3/A

Importance Score:

Aptose Biosciences Amends Acquisition Agreement, Extends Go-Private Transaction Deadline

Price at Filing: $1.62

Real-time Price: $1.69

Change: +$0.070 (+4%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Feb 23, 2026, 8:14 PM EST

Filing Type: DEFM14A

Importance Score:

Aptose Biosciences Files Definitive Proxy for Acquisition by Hanmi Pharmaceutical, Sets Shareholder Vote

Price at Filing: $1.62

Real-time Price: $1.69

Change: +$0.070 (+4%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Feb 17, 2026, 6:13 AM EST

Filing Type: SC 13E3/A

Importance Score:

Aptose Biosciences Files Second Amendment to Going-Private Transaction Statement for Hanmi Acquisition

Price at Filing: $1.67

Real-time Price: $1.69

Change: +$0.020 (+1%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Feb 17, 2026, 6:06 AM EST

Filing Type: PRER14A

Importance Score:

Aptose Biosciences Files Definitive Proxy for Hanmi Acquisition, Citing Insolvency Risk if Deal Fails

Price at Filing: $1.67

Real-time Price: $1.69

Change: +$0.020 (+1%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Feb 09, 2026, 6:15 AM EST

Filing Type: SC 13E3/A

Importance Score:

Aptose Biosciences Amends Going-Private Transaction Details, Outlines Investor Rights for Acquirer

Price at Filing: $1.66

Real-time Price: $1.69

Change: +$0.030 (+2%)

Market Cap: $4.314M

Sentiment: Neutral

View Wiseek Article

APTOF

Jan 14, 2026, 9:26 PM EST

Filing Type: SC 13E3

Importance Score:

Aptose Biosciences to Go Private in C$2.41 Per Share Arrangement

Price at Filing: $1.57

Real-time Price: $1.69

Change: +$0.1175 (+7%)

Market Cap: $4.314M

Sentiment: Negative

View Wiseek Article

APTOF

Jan 14, 2026, 9:23 PM EST

Filing Type: PRER14A

Importance Score:

Aptose Biosciences to be Acquired by Hanmi Pharmaceutical Subsidiary for C$2.41 Per Share, Mitigating Insolvency Risk

Price at Filing: $1.57

Real-time Price: $1.69

Change: +$0.1175 (+7%)

Market Cap: $4.314M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile